Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2025-12-25 @ 9:55 PM
Study NCT ID:
NCT00879658
Status:
COMPLETED
Last Update Posted:
2020-01-13
First Post:
2009-04-09
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03-30
Start Date Type:
ACTUAL
Primary Completion Date:
2011-05-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-05-04
Completion Date Type:
ACTUAL
First Submit Date:
2009-04-09
First Submit QC Date:
None
Study First Post Date:
2009-04-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-10-30
Results First Submit QC Date:
None
Results First Post Date:
2020-01-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2012-08-01
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2019-12-26
Last Update Post Date:
2020-01-13
Last Update Post Date Type:
ACTUAL